Physician profile
Thomas J Moore
NPI 1235211616
$4,819.71
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $884 · 2021: $851 · 2022: $1,171 · 2023: $895 · 2024: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,072.87 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,008.30 | 2019-2024 | |
| Janssen Biotech, INC. | $733.55 | 2019-2024 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $380.01 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $369.47 | 2019-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $200.68 | 2022-2024 | Dupixent |
| Genzyme Corporation | $200.34 | 2022-2024 | |
| Echosens North America, INC. | $157.43 | 2024 | Fibroscan |
| Biohaven Pharmaceutical Holding Company LTD. | $130.05 | 2022 | |
| Daiichi Sankyo INC. | $103.79 | 2020-2023 | Injectafer |
| Amgen INC. | $101.01 | 2019-2021 | |
| Allergan, INC. | $72.74 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.51 | 2022-2024 | |
| Amarin Pharma, INC. | $55.32 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.31 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.03 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $30.96 | 2020-2022 | |
| Qol Medical, LLC | $20.41 | 2024 | Sucraid |
| Redhill Biopharma INC. | $20.15 | 2022 | |
| Lilly USA, LLC | $18.78 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.